Evidence map›Paper›PMID 33777027›Full record

ReviewFrontiers in immunology2021

Flipside of the Coin: Iron Deficiency and Colorectal Cancer.

Aysegül Aksan, Karima Farrag, Sami Aksan, Oliver Schroeder, Jürgen Stein

Open access · goldAbstract readReview
In one paragraph

Review in Frontiers in immunology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.

0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
8.5field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

44 citing papers in PubMed, 74 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Zinc, copper, copper-to-zinc ratio, and other biometals in blood serum and tumor tissue of patients with colorectal cancer.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025
    Article
  11. Review
  12. Article
  13. Review
  14. Iron and Cancer.Advances in experimental medicine and biology · 2025
    Review
  15. Article
  16. Article
  17. Enhanced CRC Growth in Iron-Rich Environment, Facts and Speculations.International journal of molecular sciences · 2024
    Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 2 institutions in 1 country.

Aysegül AksanInstitute of Nutritional Science, Justus-Liebig University, Giessen, Germany.
Karima FarragInterdisziplinäres Crohn Colitis Centrum, Rhein-Main, Frankfurt, Germany.
Sami AksanInterdisziplinäres Crohn Colitis Centrum, Rhein-Main, Frankfurt, Germany.
Oliver SchroederInterdisziplinäres Crohn Colitis Centrum, Rhein-Main, Frankfurt, Germany.
Jürgen SteinInstitute of Pharmaceutical Chemistry, Goethe University, Frankfurt, Germany.
Krankenhaus Sachsenhausen · DEUniversity of Giessen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Iron deficiency, with or without anemia, is the most frequent hematological manifestation in individuals with cancer, and is especially common in patients with colorectal cancer. Iron is a vital micronutrient that plays an essential role in many biological functions, in the context of which it has been found to be intimately linked to cancer biology. To date, however, whereas a large number of studies have comprehensively investigated and reviewed the effects of excess iron on cancer initiation and progression, potential interrelations of iron deficiency with cancer have been largely neglected and are not well-defined. Emerging evidence indicates that reduced iron intake and low systemic iron levels are associated with the pathogenesis of colorectal cancer, suggesting that optimal iron intake must be carefully balanced to avoid both iron deficiency and iron excess. Since iron is vital in the maintenance of immunological functions, insufficient iron availability may enhance oncogenicity by impairing immunosurveillance for neoplastic changes and potentially altering the tumor immune microenvironment. Data from clinical studies support these concepts, showing that iron deficiency is associated with inferior outcomes and reduced response to therapy in patients with colorectal cancer. Here, we elucidate cancer-related effects of iron deficiency, examine preclinical and clinical evidence of its role in tumorigenesis, cancer progression and treatment response. and highlight the importance of adequate iron supplementation to limit these outcomes.

Indexed as

Anemia, Iron-DeficiencyAnimalsCell Transformation, NeoplasticColorectal NeoplasmsEpigenesis, GeneticGene Expression Regulation, NeoplasticHumansIronIron CompoundsOxidative StressTumor EscapeTumor MicroenvironmentIronIron Compoundscolorectal cancerimmune host defenseintravenous iron therapyiron deficiencyiron deficiency anemia

Identifiers

PMID33777027
PMCPMC7991591
OpenAlexW3133568782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.